How do the various antidepressant classes compare in terms of efficacy, tolerability, dosing recommendations, and side‑effect profiles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Comparison of Antidepressants

Select second-generation antidepressants based on side effect profiles, cost, and patient preferences—not efficacy, as all demonstrate equivalent effectiveness for treating major depression. 1

Efficacy: No Clinically Meaningful Differences

All second-generation antidepressants show comparable efficacy for acute treatment of major depressive disorder, with no antidepressant demonstrating superior effectiveness that justifies selection based on efficacy alone 1. While some large network meta-analyses suggest statistical differences favoring escitalopram, sertraline, mirtazapine, and venlafaxine over others 2, 3, these differences are small and likely not clinically meaningful in real-world practice 1.

Key efficacy facts:

  • Response rates: 46-62% across all agents (38% fail to respond within 6-12 weeks) 1
  • Remission rates: 46% fail to achieve remission 1
  • Efficacy is equivalent across age groups, sex, race/ethnicity, and comorbid conditions 1
  • Onset of action: Mirtazapine may work faster than fluoxetine, paroxetine, or sertraline 1

Side Effect Profiles: The Critical Differentiator

Since efficacy is equivalent, choose antidepressants by matching side effect profiles to patient characteristics:

Sexual Dysfunction

  • Lowest risk: Bupropion (significantly lower than SSRIs) 1
  • Highest risk: Paroxetine (worse than fluoxetine, fluvoxamine, nefazodone, sertraline) 1
  • Moderate risk: All other SSRIs

Gastrointestinal Effects

  • Highest nausea/vomiting: Venlafaxine 1
  • Highest diarrhea: Sertraline 1
  • Nausea/vomiting are the most common reasons for discontinuation 1

Weight and Metabolic Effects

  • Highest weight gain: Mirtazapine and paroxetine 1
  • Weight neutral: Sertraline, trazodone, venlafaxine, bupropion 1

Sedation

  • Most sedating: Trazodone, mirtazapine 1
  • Least sedating/activating: Bupropion, fluoxetine 4

Suicidality Risk

  • All SSRIs carry increased risk for nonfatal suicide attempts compared to placebo (OR 1.57-2.25) 1
  • No differences between individual second-generation antidepressants 1
  • Monitor all patients within 1-2 weeks of initiation, as risk is highest in first 1-2 months 1

Other Serious Adverse Events

  • Seizure risk: Bupropion (avoid in seizure disorders) 1, 4
  • Cardiovascular risk: Venlafaxine (increased blood pressure/heart rate) 1
  • Hepatotoxicity: Nefazodone 1, 4

Optimal Dosing Recommendations

For SSRIs, the lower range of licensed doses (20-40 mg fluoxetine equivalents) achieves optimal balance between efficacy, tolerability, and acceptability 5. Higher doses increase side effects without proportional efficacy gains:

  • Fluoxetine: 20 mg daily (10 mg in elderly)
  • Sertraline: 50-100 mg daily (25-50 mg starting)
  • Citalopram: 20 mg daily (10 mg in elderly)
  • Escitalopram: 10 mg daily
  • Paroxetine: 20 mg daily (10 mg in elderly)

For venlafaxine, efficacy increases up to 75-150 mg, then plateaus 5. For mirtazapine, efficacy peaks at 30 mg then decreases 5.

Acceptability and Tolerability Rankings

Best acceptability (lowest dropout rates): Escitalopram, sertraline, citalopram, fluoxetine, agomelatine 2, 3

Worst acceptability (highest dropout rates): Reboxetine, clomipramine, duloxetine, fluvoxamine, trazodone, venlafaxine 2, 3

Clinical Algorithm for Selection

  1. First-line choice: Sertraline or escitalopram—best balance of efficacy, acceptability, and cost 2, 3

  2. If sexual dysfunction is a concern: Bupropion 1

  3. If insomnia/agitation predominates: Mirtazapine or trazodone 1, 4

  4. If apathy/low energy predominates: Bupropion or venlafaxine 4

  5. If weight gain is unacceptable: Avoid mirtazapine and paroxetine; choose bupropion, sertraline, or venlafaxine 1

  6. In elderly patients: Start at half the standard dose; prefer sertraline, citalopram, or escitalopram for better tolerability 1

Treatment Monitoring and Modification

Assess response within 1-2 weeks of initiation to monitor for suicidality, agitation, or intolerable side effects 1. If inadequate response after 6-8 weeks, modify treatment by switching antidepressants or augmenting with another agent 1. Evidence shows no superiority of switching versus augmentation strategies 6.

Continue treatment 4-9 months after first episode remission; longer duration for recurrent depression 1.

Critical Pitfalls to Avoid

  • Do not select based on efficacy claims—marketing often overstates small statistical differences that lack clinical significance 1
  • Do not abruptly discontinue—taper slowly over weeks to months to avoid withdrawal symptoms, especially with paroxetine, venlafaxine, and duloxetine 7, 8
  • Do not ignore suicide risk monitoring—all antidepressants require close surveillance in first 1-2 months 1
  • Do not exceed optimal dose ranges—higher SSRI doses increase side effects without improving efficacy 5

References

7
Research

Stopping antidepressants: when and how.

Australian prescriber, 2026

Related Questions

What is the ranking of antidepressants based on long‑term tolerability in typical adult patients?
What are the appropriate oral liquid formulations and dosing for a 39-year-old woman with moderate major depressive disorder and generalized anxiety disorder for fluoxetine, escitalopram, sertraline, paroxetine (Paxil), and citalopram (Celexa)?
How should a 32-year-old who abruptly stopped long-term sertraline 200 mg be managed?
Should a 50-year-old patient who has been taking duloxetine (Cymbalta) 30 mg daily for one month be tapered before discontinuation?
How should a 40-year-old male who has been self-tapering venlafaxine extended-release 150 mg every other day for 5 weeks be placed on a hyperbolic taper?
In an adult with acute low back pain and no contraindications to NSAIDs, is ketoprofen or dexamethasone the preferred treatment?
What is the best evidence for the effectiveness of antidepressants in treating major depressive disorder?
What is the appropriate management for a 56-year-old male presenting with three days of fever, purulent sputum, and chest radiograph showing consolidation?
How many hours per day on average does a patient with chronic kidney disease (CKD) stage 3 need to spend on disease management?
Can a patient who consistently responds to oral dipirona (metamizole) 1 g and ibuprofen be given dipirona intramuscularly and diclofenac intramuscularly?
Which medication, dexamethasone or diclofenac, is more appropriate for treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.